Fractyl Health Announces Groundbreaking Clinical Trial Results for Revita® Procedure, Showing Sustained Weight Loss After GLP-1 Drug Discontinuation
I'm PortAI, I can summarize articles.
Fractyl Health Inc. announced results from the REMAIN-1 Midpoint Cohort, a clinical study on the Revita® procedure for maintaining weight after GLP-1 drug discontinuation. Patients treated with Revita lost an additional 2.5% of body weight at three months, while the sham group regained 10% (p=0.014). The procedure showed a favorable safety profile. Upcoming milestones include six-month data in Q1 2026 and topline data from the pivotal cohort later in 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments